A vida na Bio-Rad

Bio-Rad Rides Tour de Cure in Support of the American Diabetes Association

October 11, 2023

Video: Watch our team at Tour de Cure 2023!

More than 30 Bio-Rad employees, family, and friends came together on Sunday, October 1 for the Northern California Tour de Cure, a bike ride that aims to find a cure for diabetes. Employees have raised over $15,000 for this year’s event, with a $25,000 sponsorship also planned. 

For many employees, the Tour de Cure is a source of pride each and every year. “I've been doing the Tour de Cure ever since I joined Bio-Rad about ten years ago,” says Brian Wilson, Director of R&D Engineering for Bio-Rad's Life Science Group. “I’ve had the opportunity to ride their 100-mile bicycle ride and their 64-mile bicycle routes.” 

Team Captain Ragani Harris has also been involved with the event for several years and is proud of the impact she has made with others at Bio-Rad. “For more than a decade, I've been riding with the team, serving on the Tour de Cure committee for eight years, and captaining the team for five years,” Ragani says. “I've had the privilege of working with leaders from our Company and the ADA, witnessing first-hand how we play a role in the success of this event.”  

The Tour de Cure’s ongoing efforts to find a cure for diabetes align closely to Bio-Rad's mission to advance science and save lives, together. We have been participating at Tour de Cure for more than 25 years, contributing more than $1 million to the American Diabetes Association during this time.  

In the coming years, we hope to assemble larger teams to maximize the impact we can make together. “We would love to have more employees from Bio-Rad, their families, and our extended communities experience this impactful ride with us,” Ragani says.  

If you are interested in joining our team, please look for Team Bio-Rad on the Tour de Cure website next fall. If you'd like to donate to our team or one of our riders, please click here. 

Looking for a company where you can make an impact? View our open roles.